...
机译:Avelumab Plus Axitinib对舒尼替尼用于晚期肾细胞癌
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10065 USA;
Private Med Inst Euromedserv St Petersburg Russia;
Netherlands Canc Inst Amsterdam Netherlands;
Cleveland Clin Cleveland OH 44106 USA;
Inst Gustave Roussy Villejuif France;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
Univ Glasgow Beatson West Scotland Canc Ctr Glasgow Lanark Scotland;
British Columbia Canc Agcy Vancouver BC Canada;
Univ Lyon Ctr Leon Berard Lyon France;
Osaka Univ Hosp Osaka Japan;
Univ Ulsan Coll Med Asan Med Ctr Seoul South Korea;
Nonstate Hlth Inst Rd Clin Hosp Russian Railways St Petersburg Russia;
McGill Univ Lady Davis Inst Montreal PQ Canada;
Macquarie Univ Sydney NSW Australia;
Med Univ Vienna Div Clin Oncol Dept Med 1 Vienna Austria;
Royal Marsden NHS Fdn Trust London England;
Georgetown Lombardi Comprehens Canc Ctr Washington DC USA;
Univ Tubingen Dept Urol Tubingen Germany;
Moscow Sci Res Oncol Inst Moscow Russia;
Pfizer Cambridge MA USA;
Pfizer Milan Italy;
Pfizer San Diego CA USA;
Pfizer Cambridge MA USA;
Pfizer Italia Milan Italy;
Pfizer New York NY USA;
Pfizer Groton CT USA;
Pfizer Milan Italy;
Dana Farber Canc Inst Lank Ctr Genitourinary Oncol Boston MA 02115 USA;
机译:Avelumab Plus Axitinib对舒尼替尼用于晚期肾细胞癌
机译:Re:Pembrolizumab Plus Axitinib与unitinib进行晚期肾细胞癌
机译:Re:Avelumab Plus Axitinib作为先进透明细胞肾细胞癌(标枪肾100)的一线治疗的初步结果:OpenLabel,剂量寻找和剂量扩展,第1B期试验
机译:新的DCE-MRI参数可量化舒尼替尼治疗在肾癌肿瘤中诱导的血管变化
机译:晚期浆液性卵巢癌的同型TP53突变。
机译:成本效益分析:一线Avelumab加阿昔替尼与舒尼替尼治疗晚期肾细胞癌
机译:一种成本效益分析:一线Avelumab Plus Axitinib与仙醇进行晚期肾细胞癌